Funding Archives

gastrointestinal disease heptares imperial2 1

News and Trends 7 Jul 2022

French Juvisé buys gastro product in €400M finance deal

French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical company Abbvie. Juvisé negotiated financing of €400 million ($408 million) with Société Générale as part of the deal and also the refinancing of its existing debt. Pylera is an antimicrobial tri-therapy that helps gastro-intestinal Helicobacter pylori infections. Lazard and Latham […]

July 7, 2022 - 2 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

Funding doubled for company working on breakthrough auto-immune disease therapeutics

A Paris-based biotech company developing products for auto-immune diseases, announced today (June 30) that it has almost doubled its initial funding from two companies. The initial funding for Ermium Therapeutics of €6.3 million ($6.57 million) now stands at €12.3 million ($12.83 million) and has been supplied by Kurma Partners and Fountain Healthcare Partners. Ermium discovers […]

June 30, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Osivax gets €10M influenza vaccine grant

A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to support a vaccine against influenza. The biopharma company develops vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases. It announced today (June 23) that it has secured the funds from Bpifrance to support the further clinical development […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Jun 2022

Shanghai biotech secures $80 million to advance products

A bio-manufacturing company based in Shanghai has bagged $80 million in funding to advance its bio-based supplies. Mojia Biotech said it would use the funds to commercialize its Viridimin brand of animal-feed additives, scale up manufacturing capacity for Aliphane series of bio-based materials, advance its product pipeline and expand its global research and development capabilities. […]

June 23, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Jun 2022

Millions invested for progression of Lyme disease vaccine

Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. A deal has been struck with Valneva SE that will see the start of the phase 3 study of the disease’s vaccine candidate, VLA15. This is scheduled for the third quarter of this year. The investment will represent 8.1% of […]

June 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 15 Jun 2022

Biotech companies to benefit from Third Rock Ventures $1.1B fund

U.S. company Third Rock Ventures has closed Third Rock Ventures Fund VI, raising $1.1 billion. Fund VI will continue Third Rock’s core strategy to discover, launch and build new companies focused on improving the lives of patients. “An important differentiator for Third Rock is the strength and maturity of our ideation ecosystem,” said Reid Huber, […]

June 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

New Forbion life sciences fund hits €470M

European life sciences venture capital firm Forbion, has announced the first €470M ($500M) close of its Forbion Growth Opportunities Fund II. The fund will focus on investing in late-stage European life sciences companies. The new fund has attracted several new institutional investors, including pension funds PME and PMT, the Ewing Marion Kauffman Foundation and Reggeborgh, […]

June 9, 2022 - 4 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us